Patents Assigned to Evaxion Biotech A/S
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 12226469
    Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 18, 2025
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Chimeric proteins for inducing immunity towards infection with
    Patent number: 12209110
    Abstract: Disclosed is chimeric polypeptides derived from S. aureus proteins having SEQ ID NOs: 1-9 and 139-146. The chimeric polypeptides are useful as immunogens for providing protective immunity against S. aureus infection. Also disclosed are compositions, methods of treatment and prophylaxis, nucleic acids and vectors comprising the nucleic acids.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: January 28, 2025
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson, Jens Kringelum
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 12006342
    Abstract: Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: June 11, 2024
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Peptides derived from and their use in vaccination
    Patent number: 11857615
    Abstract: The present invention relates to proteins derived from Acinetobacter baumanii, nucleic acids encoding the proteins, antibodies specific for the proteins as well as methods of therapy, prophylaxis, and diagnosis that utilise the proteins, nucleic acids, and antibodies.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: January 2, 2024
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 11807669
    Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: November 7, 2023
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Vaccines targeting
    Patent number: 11718648
    Abstract: Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 8, 2023
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Chimeric proteins for inducing immunity towards infection with
    Patent number: 11414464
    Abstract: Disclosed is chimeric polypeptides derived from S. aureus proteins having SEQ ID NOs: 1-9 and 139-146. The chimeric polypeptides are useful as immunogens for providing protective immunity against S. aureus infection. Also disclosed are compositions, methods of treatment and prophylaxis, nucleic acids and vectors comprising the nucleic acids.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: August 16, 2022
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson, Jens Kringelum
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 11052145
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson